A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
780estimated
Sites
90
Countries
Argentina, Canada, Germany +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-01 | actual | When the study began enrolling |
| Primary completion | 2025-10-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Interventions
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Antihyperglycemic medication
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Hemoglobin A1c (HbA1c)
measured Baseline, Week 104
Publications
- PMID 42184419 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed